Risk factors
Capricor Therapeutics (CAPR) risk factors
Item 1A of every Capricor Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors88 risks14 new11 dropped25 reworded
Capricor highlighted new risks regarding $318.1 million in cash, foreign tariffs, most-favored-nation drug pricing models, and San Diego manufacturing.
Filed Mar 17, 2026 - FY2024 10-K risk factors85 risks
Capricor Therapeutics faces high reliance on its lead cell therapy product deramiocel for Duchenne muscular dystrophy.
Filed Mar 26, 2025